FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says

 
• By Cathy Kelly
  
PBMs And Patents Are Two Important Drug Pricing Issues For Linda Khan and the FTC.

More from Market Access

More from Pink Sheet